EHA and ASCO 2023 highlights: promising treatments in AML, MDS, and ALL

Highlights in AML and MDS from EHA 2022Подробнее

Insights into the future of AML therapy: the increasing use of targeted agentsПодробнее

A Patients Perspective on MDS and AML: Updates from EHA ASCOПодробнее

Top highlights from ASCO & EHA 2023Подробнее

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?Подробнее

What were your highlights from EHA 2023?Подробнее

2019 Research Updates on MDS and AML from EHA and ASCOПодробнее

Post ASCO/EHA 2023 Roundtable Discussion on the latest updates in MDSПодробнее

Updates in AML Treatment and Research From ASCO 2023Подробнее

Highlights at ASCO 2023Подробнее

Looking forward to EHA 2023: CARTITUDE-4, bispecifics, novel combinations and moreПодробнее

Non Transplant Treatments for MDS & Secondary AML (Co-Chair Summary)Подробнее

Differences and similarities between MDS and AML & how this can inform treatment decisionsПодробнее

Ziftomenib: mechanism of action and promising results in patients with KMT2Ar or NPM1m AMLПодробнее

Promising novel agents in AML: menin inhibitorsПодробнее

ICAHO20 ASCO Direct™ Highlights - Rapid-Fire Q&A MDS/MPN/AML - Dr. Anna HalpernПодробнее

Mid-Year Updates in AML Research | Dr. Daver EHA 2022 with Q&A #AMLПодробнее

The importance risk stratification to enable risk-adapted therapy in MDS & CMMLПодробнее